Alimentiv Inc., a prominent Contract Research Organization specializing in GI-related therapeutics, has announced the inclusion of new scientific advisors to its scientific advisory board. These advisors are globally acknowledged experts in designing and conducting clinical research in Inflammatory Bowel Disease (IBD). Their significant contributions have been pivotal in advancing the development of innovative IBD therapies and enhancing patient outcomes.
Dr./Prof. Remo Panaccione: A Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He is also the Dean of MD Admissions and Director of the IBD Fellowship Program. Dr. Panaccione has co-authored numerous publications and has been a principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in patients with IBD.
Dr. Bruce Sands, MD, MS: Recognized as the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands is renowned for his clinical investigations of new therapeutics for inflammatory bowel diseases.
Alimentiv is a global gastroenterology-focused contract research organization (CRO) offering a range of services, including clinical trials, central image management, precision medicine, and real-world evidence services.
Over the past two decades, Alimentiv has emerged as a recognized expert in clinical trial design, central image management solutions, and precision medicine for drug development in GI.
The company collaborates with leading universities and academic institutions worldwide and works with several top pharmaceutical and biotechnology organizations.